Qualigen Shares Surge 94.72% on $430M Volume Spike as Rare Disease Drug Moves to Phase III Ranks 258th in Market Activity

On September 22, 2025, , . The abrupt spike in volume and price drew immediate attention from market participants.

Recent developments suggest a potential catalyst for the rally. , with preliminary data expected by year-end. Analysts highlighted the therapy’s and competitive differentiation in a niche market segment. Additionally, .

Investor sentiment appears influenced by renewed interest in the biotech sector following a broader market rebound. However, . .

To run this back-test rigorously I need to clarify a few details that aren’t fully specified yet: Market universe, ranking logic & trade timing, weighting scheme, and transaction costs & slippage. Once we lock in these points I can fetch the data and run the back-test.